CSF3 and plasma cell myeloma: In December 2008, AMD3100 was approved by the FDA for hematopoietic stem and progenitor cell (HSPC) mobilization in combination with granulocyte colony-stimulating factor (G-CSF) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma undergoing autologous bone marrow transplantation.